Changing landscape of hereditary breast and ovarian cancer germline genetic testing in Australia.
Intern Med J
; 48(10): 1269-1272, 2018 10.
Article
en En
| MEDLINE
| ID: mdl-30288903
ABSTRACT
Federal funding for germline genetic testing in hereditary breast and ovarian cancer (HBOC) was recently introduced. Germline testing for HBOC under Medicare Benefits Schedule items 73296/73297 can be requested by any specialist, whereas the previous state- and territory-funded testing was limited to those operating within a familial cancer service. The impact of this decentralisation of HBOC testing on health and economic outcomes is uncertain, primarily as it has potential to significantly disrupt the clinical framework that generated the evidence used to justify clinical implementation of the Medicare Benefits Schedules.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias Ováricas
/
Neoplasias de la Mama
/
Pruebas Genéticas
/
Predisposición Genética a la Enfermedad
/
Síndrome de Cáncer de Mama y Ovario Hereditario
Tipo de estudio:
Etiology_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Female
/
Humans
País como asunto:
Oceania
Idioma:
En
Año:
2018
Tipo del documento:
Article